Literature DB >> 29409822

Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.

Susana A Palma-Duran1, Meropi D Kontogianni2, Antonis Vlassopoulos1, Shudong Zhao1, Aikaterini Margariti3, Michael Georgoulis2, George Papatheodoridis3, Emilie Combet4.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a serious health problem affecting ~25% of the global population. While NAFLD pathogenesis is still unclear, multiple NAFLD parameters, including reduced insulin sensitivity, impaired glucose metabolism and increased oxidative stress are hypothesised to foster the formation of advanced glycation end-products (AGEs). Given the link of AGEs with end organ damage, there is scope to examine the role of the AGE/RAGE axis activation in liver injury and NAFLD.
METHODS: Age, sex and body mass index matched normo-glycemic NAFLD adults (n = 58) and healthy controls (n = 58) were enrolled in the study. AGEs were analysed by liquid chromatography-mass spectrometry (CML, CEL), fluorescence (pentosidine, AGE fluorescence), colorimetry (fructosamine) and ELISA (sRAGE). Their association with liver function, inflammation, fibrosis and stage of NAFLD was examined.
RESULTS: Early and advanced glycation end-products, except Nε-carboxymethyl-L-lysine (CML), were 10-30% higher, sRAGE levels 1.7-fold lower, and glycation/sRAGE ratios 4-fold higher in the NAFLD cases compared to controls. While AGEs presented weak to moderate correlations with indices of liver function and damage (AST/ALT, HOMA-IR, TNF-α and TGF-β1), including sRAGE to characterize the AGEs/sRAGE axis strengthened the associations observed. High glycation/sRAGE ratios were associated with 1.3 to 14-fold likelihood of lower AST/ALT ratios. The sum of AGEs/sRAGE ratios accurately distinguished between healthy controls and NAFLD patients (area under the curve of 0.85). Elevated AGEs/sRAGE (>7.8 mmol/pmol) was associated with a 12-fold likelihood of the presence of NAFLD.
CONCLUSION: These findings strengthen the involvement of AGEs-RAGE axis in liver injury and the pathogenesis of NAFLD.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; CML; Glycation; Liver; NAFLD; sRAGE

Mesh:

Substances:

Year:  2018        PMID: 29409822     DOI: 10.1016/j.metabol.2018.01.023

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  19 in total

Review 1.  Nonalcoholic fatty liver disease: lifestyle and quality of life.

Authors:  Ilias Vachliotis; Antonis Goulas; Paraskevi Papaioannidou; Stergios A Polyzos
Journal:  Hormones (Athens)       Date:  2021-12-01       Impact factor: 2.885

Review 2.  Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease.

Authors:  Seigmund Wai Tsuen Lai; Edwin De Jesus Lopez Gonzalez; Tala Zoukari; Priscilla Ki; Sarah C Shuck
Journal:  Chem Res Toxicol       Date:  2022-10-05       Impact factor: 3.973

3.  Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.

Authors:  Jacopo Sabbatinelli; Stefania Castiglione; Federica Macrì; Angelica Giuliani; Deborah Ramini; Maria Cristina Vinci; Elena Tortato; Anna Rita Bonfigli; Fabiola Olivieri; Angela Raucci
Journal:  Cardiovasc Diabetol       Date:  2022-06-06       Impact factor: 8.949

4.  Association of meat consumption with NAFLD risk and liver-related biochemical indexes in older Chinese: a cross-sectional study.

Authors:  Hewei Peng; Xiaoxu Xie; Xinting Pan; Jing Zheng; Yidan Zeng; Xiaoling Cai; Zhijian Hu; Xian-E Peng
Journal:  BMC Gastroenterol       Date:  2021-05-17       Impact factor: 3.067

5.  Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study.

Authors:  Marci Laudenslager; Mariana Lazo; Dan Wang; Elizabeth Selvin; Po-Hung Chen; James S Pankow; Jeanne M Clark
Journal:  Dig Liver Dis       Date:  2021-02-24       Impact factor: 5.165

6.  Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease.

Authors:  Dana Ivancovsky-Wajcman; Shira Zelber-Sagi; Naomi Fliss Isakov; Muriel Webb; Meir Zemel; Oren Shibolet; Revital Kariv
Journal:  Clin Transl Gastroenterol       Date:  2019-05-22       Impact factor: 4.488

Review 7.  RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Kamyar Asadipooya; Kamran B Lankarani; Rishi Raj; Mohammadreza Kalantarhormozi
Journal:  Int J Endocrinol       Date:  2019-09-18       Impact factor: 3.257

8.  Corrigendum: Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?

Authors:  Chinedum Eleazu; Norsuhana Omar; Oon Zhi Lim; Boon Seng Yeoh; Nik Hazlina Nik Hussain; Mahaneem Mohamed
Journal:  Front Physiol       Date:  2019-08-07       Impact factor: 4.566

Review 9.  Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches.

Authors:  Angelo Armandi; Jörn M Schattenberg
Journal:  Nutrients       Date:  2021-06-08       Impact factor: 5.717

10.  l-Theanine Ameliorates d-Galactose-Induced Brain Damage in Rats via Inhibiting AGE Formation and Regulating Sirtuin1 and BDNF Signaling Pathways.

Authors:  Li Zeng; Ling Lin; Ling Chen; Wenjun Xiao; Zhihua Gong
Journal:  Oxid Med Cell Longev       Date:  2021-07-19       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.